SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!SARS-CoV-2 오미크론(B.1.1.529) 변형: 기다릴 시간이 없습니다!Article Published on 2022-05-112022-09-11 Journal: Acta bio-medica : Atenei Parmensis [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect B.1.1.529 coronavirus coronavirus disease Coronavirus disease 2019 disease Health Organization help Immunity International Mutation NEWS omicron outbreak pandemic raised SARS-CoV-2 Spread spreading the disease time variant VoC WHO World Health Organization [DOI] 10.23750/abm.v93i2.12712 PMC 바로가기 [Article Type] Article
How national leaders keep ‘us’ safe: A longitudinal, four-nation study exploring the role of identity leadership as a predictor of adherence to COVID-19 non-pharmaceutical interventionsObservational Study Published on 2022-05-102022-10-04 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI Chancellor China conducted country COVID-19 COVID-19 pandemic Data collection example Face masks Germany Health Health policy identity Intervention inventory leadership less National NPI NPIs predicted President Public public health recommendations time turn USA was related women [DOI] 10.1136/bmjopen-2021-054980 PMC 바로가기 [Article Type] Observational Study
Rapid and Accurate Identification of SARS-CoV-2 Variants Using Real Time PCR AssaysReal Time PCR 어세이를 사용한 SARS-CoV-2 변이체의 빠르고 정확한 식별Article Published on 2022-05-102022-09-11 Journal: Frontiers in Cellular and Infection Microbiology [Category] Coronavirus, COVID19(2023년), SARS, 변종, 치료기술, 치료제, [키워드] allele Alpha B.1.1.7 B.1.351 B.1.617.2 Beta blinded Combination correlated COVID-19 COVID-19 pandemic Delta delta variant Diagnosis diagnostic testing disease severity E484K effort Epidemiology evade Gamma Genomic surveillance genotyping help host immunity identification Laboratory lack Lineage management Mutation N501Y omicron P.1 P681R Patient Patient management PCR positive primer Rapid real-time RT-PCR resource reverse transcription-PCR routine diagnostic testing RT-PCR S982A SAR-CoV-2 SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants screened Sequencing specimen specimens spike gene Surveillance susceptibility tested the SARS-CoV-2 Therapeutics These data time Transmissibility variant variants Viral variants WGS while whole-genome sequencing [DOI] 10.3389/fcimb.2022.894613 PMC 바로가기 [Article Type] Article
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso부르키나파소에서 하이드록시클로로퀸 또는 클로로퀸과 아지트로마이신 조합으로 치료한 COVID-19 입원 환자 및 외래 환자의 회복 시간, 악화 및 사망 평가Observational Study Published on 2022-05-012022-09-11 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 95% CI adjusted aggravation assessment association Azithromycin Burkina Faso Chloroquine Chloroquine phosphate clearance death disease dose fatality Follow-up Hydroxychloroquine hydroxychloroquine plus azithromycin information Inpatient Inpatients lower risk multivariable no significant difference no significant differences observational study outcome Outpatient Patient patients with COVID-19 phosphate Poisson model provided receiving retrospective SRAS-CoV-2 statistical time Time to recovery treated Treatment viral clearance Virological with COVID-19 worsening [DOI] 10.1016/j.ijid.2022.02.034 PMC 바로가기 [Article Type] Observational Study
Comparison of chest CT severity scoring systems for COVID-19COVID-19에 대한 흉부 CT 중증도 점수 시스템 비교Article Published on 2022-05-012022-09-11 Journal: European Radiology [Category] COVID19(2023년), SARS, 치료기술, [키워드] abnormality Accuracy asked AUC calculated Chest CT Clinical severity Computed tomography Computed tomography, X-ray coronavirus COVID-19 CT chest cutoff value demonstrated diagnostic Diagnostic accuracy discrimination female FIVE highest Interpretation lung lung involvement male observation Patient PCR-confirmed PCR-confirmed COVID-19 pulmonary involvement Quantitative reported Reporting Retrospective study ROC Curve ROC curves SARS-CoV-2 scoring system Severe case severe cases severity significantly specificity statistically significant time tomography TSS X-ray [DOI] 10.1007/s00330-021-08432-5 PMC 바로가기 [Article Type] Article
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational StudyObservational Study Published on 2022-05-012022-10-05 Journal: Paediatric drugs [Category] 임상, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Admission age Clinical improvement Clinical outcome controls COVID-19 COVID-19 patient COVID-19 patients cumulative early treatment evaluate exposure groups hazard ratio HIV-1 Hong Kong hospital hospital discharge Human Hyperinflammatory syndrome Infection Linear model Lopinavir/ritonavir MERS Middle East observational study outcomes Patient patients pediatric Pediatric patient performed pharmacological treatment positive Randomized controlled trial receiving respiratory Seroconversion time Treatment were assessed [DOI] 10.1007/s40272-022-00500-7 PMC 바로가기 [Article Type] Observational Study
The Emergence of Omicron: Challenging Times Are Here Again!오미크론의 출현: 도전적인 시대가 다시 도래했습니다!Review Published on 2022-05-012022-09-11 Journal: Indian journal of pediatrics [Category] COVID19(2023년), SARS, 변종, [키워드] Alpha average Beta booster vaccinations Care caused children consequence country COVID COVID-19 death disease doubling driving Effect emergence equity expected Government Health Health care Hospitalization imperative India indirect effect indirect effects Infection lockdowns Mental Mild Mutation neglect notable offer omicron Omicron variant on children other diseases other variants phylogenetically physical PROTECT reported severe disease Spread Third wave time Travel vaccination Vaccinations Vaccine variant variant of concern (VOC) variants VoC worsened [DOI] 10.1007/s12098-022-04077-4 PMC 바로가기 [Article Type] Review
Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19COVID-19로 입원한 환자를 위한 플랫폼에서 단일 클론 항체를 제거할 시간Comment Published on 2022-05-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] hospitalised monoclonal antibody Patient platform time with COVID-19 [DOI] 10.1016/S1473-3099(21)00762-3 PMC 바로가기 [Article Type] Comment
A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days비활성화 백신의 세 번째 접종은 항 SARS-CoV-2 항체의 수준과 붕괴 시간을 극적으로 증가시켰지만 다시 실망스럽게 감소했습니다: 368일 동안 18개의 연속 시점에서 전향적, 종적, 코호트 연구Article Published on 2022-04-292022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI activate administration anti-RBD anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody Anti-spike anti-Spike IgG antibody antibody levels booster dose carried conversion rate CoronaVac COVID-19 Day decay dose Efficacy evaluate FIVE fold half-life half-live half-lives IgA IgA level IgG IgM immune immune characteristics immune protection Immunity inactivated Increased Level longitudinal management much lower neutralizing antibody over Point positive positive conversion Predictive predictive values Prospective prospective cohort study regimen regimens remained response revaccination SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants second dose subset the SARS-CoV-2 time vaccination Vaccine volunteers [DOI] 10.3389/fimmu.2022.876037 PMC 바로가기 [Article Type] Article
Changes in Anti-SARS-CoV-2 IgG Subclasses over Time and in Association with Disease Severity시간 경과 및 질병 중증도와 관련된 Anti-SARS-CoV-2 IgG 하위 클래스의 변화Article Published on 2022-04-292022-09-12 Journal: Viruses [Category] COVID19(2023년), SARS, 진단, [키워드] Anti-RBD IgG antibody antiviral response association change Concentration COVID-19 COVID-19 infection COVID-19 patients high-affinity IgG IgG IgG subclasse IgG subclasses IgG1 IgG2 IgG3 IgG4 Immunity Infection late stage marker N protein produced Protein response S protein RBD SARS-CoV-2 antigen severity severity of COVID-19 statistically significant time timespan [DOI] 10.3390/v14050941 PMC 바로가기 [Article Type] Article